Table 2.
Randomized trials comparing antiPD1/PDL1 antibody vs. salvage chemotherapy.
| References | Histology | Treatment | N pts | RR | p | mPFS | p | MST | p |
|---|---|---|---|---|---|---|---|---|---|
| Brahmer et al. (29) Horn et al. (30) Vokes et al. (31) |
Squamous | Nivolumab | 135 | 20% | 0.008 | 3.5 m | <0.001 | 9.2 m 2 y 23% 3 y 16% |
<0.001 |
| Docetaxel | 137 | 9% | 2.8 m | 6.0 m 2 y 8% 3 y 6% |
|||||
| Borghaei et al. (32) Horn et al. (30) Vokes et al. (31) |
Non-squamous | Nivolumab | 292 | 19% | 0.02 | 2.3 m | 0.39 | 12.2 m 2 y 29% 3 y 18% |
0.002 |
| Docetaxel | 290 | 12% | 4.2 m | 9.4 m 2 y 16% 3 y 9% |
|||||
| Herbst et al. (33) | NSCLC PDL1≥1% |
Pembrolizumab 2 mg/kg | 345 | – | – | 3.9 m | 0.07 0.004 |
10.4 m | 0.0008 <0.0001 |
| Pembrolizumab 10 mg/kg | 346 | – | 4.0 m | 12.7 m | |||||
| Docetaxel | 343 | – | 4.0 m | 8.5 m | |||||
| Fehrenbacher et al. (34) | NSCLC | Atezolizumab | 144 | 15% | – | 2.7 m | NS | 12.6 m | 0.04 |
| Docetaxel | 143 | 15% | 3.0 m | 9.7 m | |||||
| Rittmeyer et al. (35) | NSCLC | Atezolizumab | 425 | 14% | – | 2.8 m | NS | 13.8 m | 0.0003 |
| Docetaxel | 425 | 13% | 4.0 m | 9.6 m | |||||
| Barlesi et al. (36) | NSCLC | Avelumab | 396 (264 PDL1+) |
15% (19) | 0.055 (0.01) | 2.8 m (3.4) | 0.95 (0.53) | 10.5 m (11.4) | 0.12 (0.16) |
| Docetaxel | 396 (265 PDL1+) |
11% (12) | 4.2 m (4.1) | 9.9 m (10.3) |
RR, response rate; mPFS, median progression free survival; MST, median survival time; NSCLC, non-small cell lung cancer; m, months; NS, not significant.